ModivCare Reports Third Quarter 2021 Financial Results
ModivCare Inc. (Nasdaq: MODV) reported strong financial results for Q3 2021, with revenues of $493.1 million, a 53.8% increase from Q3 2020. However, the company incurred a loss from continuing operations of $7.5 million, or $0.53 per diluted share. Adjusted EBITDA was $44.3 million, representing 9.0% of revenue, which was down from $59.3 million a year prior due to increased service costs. Significant acquisitions in September 2021, including VRI and CareFinders, aim to enhance service offerings and shareholder value.
- Revenue grew by 53.8% year-over-year to $493.1 million.
- Completed acquisition of VRI and CareFinders to strengthen market position.
- Net cash from operating activities was $174.7 million for the quarter.
- Strong financial position with $126.5 million in cash and undrawn $225 million revolving credit facility.
- Reported a loss from continuing operations of $7.5 million in Q3 2021.
- Adjusted EBITDA decreased to $44.3 million, down from $59.3 million year-over-year.
- Matrix's revenue declined by 44.2%, contributing to operating loss.
Third Quarter 2021 Highlights:
-
Revenue of
, a$493.1 million 53.8% increase as compared to in the third quarter of 2020$320.6 million -
Loss from continuing operations, net of tax, of
or a loss of$7.5 million per diluted common share$0.53 -
Adjusted EBITDA of
, Adjusted Net Income of$44.3 million and Adjusted EPS of$23.0 million $1.63 -
Net cash provided by operating activities during the quarter of
$174.7 million -
Cash and cash equivalents of
at$126.5 million September 30, 2021 , with debt outstanding related to the Senior Unsecured Notes due$500.0 million November 15, 2025 and an additional debt outstanding related to the Senior Unsecured Notes due$500.0 million October 1, 2029 -
Matrix, on a standalone basis, had a net loss of
and Adjusted EBITDA of$15.6 million $2.6 million
“We continue to make progress executing on our strategy to transform
Third Quarter 2021 Results
For the third quarter of 2021, the Company reported revenue of
Operating income was
Adjusted EBITDA was
Adjusted Net Income in the third quarter of 2021 was
Comparable Adjusted EBITDA and Adjusted Net Income for Q3 2020 were recast to show the impact of stock-based compensation and cash settled equity, which the Company is now including for the purpose of these calculations.
The quarter-over-quarter increase in revenue was primarily due to incremental revenue of
Adjusted EBITDA decreased in the third quarter of 2021 as compared to the third quarter of 2020 due to higher service expense costs associated with higher utilization and contact center activity. Adjusted EBITDA also decreased as a result of higher corporate general and administrative cost as the Company continued to make investments in its employees and technology.
Matrix Medical Network
For the third quarter of 2021, Matrix’s revenue was
For the third quarter of 2021, Matrix recorded Adjusted EBITDA of
Matrix’s Clinical Solutions business line primarily contributed to the decrease in Adjusted EBITDA. The decrease was due to a significant reduction in COVID-related vaccination and testing revenue. Additionally, Clinical Solutions made significant investments in staffing in anticipation of new business wins within the decentralized clinical trials market. The Clinical Care business line was relatively flat to prior year Adjusted EBITDA, as higher operating costs offset continued double-digit growth in health assessment volumes.
As of
Conference Call
US toll-free: 1 (877) 423 9820
International: 1 (201) 493 6749
You may also access the conference call via webcast at investors.modivcare.com, where the call also will be archived.
About
Non-GAAP Financial Measures and Adjustments
In addition to the financial measures prepared in accordance with generally accepted accounting principles in
Our non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because they are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies, and exclude expenses that may have a material impact on our reported financial results. The presentation of non-GAAP financial measures is not intended to be considered in isolation from or as a substitute for the most directly comparable financial measures prepared in accordance with GAAP. We urge you to review the reconciliations of our non-GAAP financial measures to the most directly comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements
Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictive in nature and are frequently identified by the use of terms such as “may,” “will,” “should,” “expect,” “believe,” “estimate,” “intend,” and similar words indicating possible future expectations, events or actions. Such forward-looking statements are based on current expectations, assumptions, estimates and projections about our business and our industry, and are not guarantees of our future performance. These statements are subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond our ability to control or predict, which may cause actual events to be materially different from those expressed or implied herein, including but not limited to: government or private insurance program funding reductions or limitations; alternative payment models or the transition of Medicaid and Medicare beneficiaries to Managed Care Organizations, or MCOs; our inability to control reimbursement rates received for our services; cost containment initiatives undertaken by private third-party payors; the effects of a public health emergency; inadequacies in, or security breaches of, our information technology systems, including the systems intended to protect our clients’ privacy and confidential information; any changes in the funding, financial viability or our relationships with our payors; pandemic infectious diseases, including the COVID-19 pandemic; disruptions to our contact center operations caused by health epidemics or pandemics like COVID-19; delays in collection, or non-collection, of our accounts receivable, particularly during any business integration; an impairment of our long-lived assets; any failure to maintain or to develop further reliable, efficient and secure information technology systems; an inability to attract and retain qualified employees; any acquisition or acquisition integration efforts; our contracts not surviving until the end of their stated terms, or not being renewed or extended; our failure to compete effectively in the marketplace; our not being awarded contracts through the government’s requests for proposals process, or our awarded contracts not being profitable; any failure to satisfy our contractual obligations or to maintain existing pledged performance and payment bonds; a failure to estimate accurately the cost of performing our contracts; any misclassification of the drivers we engage as independent contractors rather than as employees; significant interruptions in our communication and data services; not successfully executing on our strategies in the face of our competition; any inability to maintain relationships with existing patient referral sources; any failure to obtain the consent of the
The Company has provided additional information about the risks facing our business in our annual report on Form 10-K and subsequent filings with the
--financial tables to follow--
|
||||||||||||||||||||
Unaudited Condensed Consolidated Statements of Operations |
||||||||||||||||||||
(in thousands, except share and per share data) |
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
Three months ended |
|
Nine months ended |
||||||||||||||||
|
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||
Service revenue, net |
|
$ |
493,059 |
|
|
|
$ |
320,619 |
|
|
|
$ |
1,421,117 |
|
|
|
$ |
970,166 |
|
|
Grant income |
|
— |
|
|
|
— |
|
|
|
3,500 |
|
|
|
— |
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
||||||||||||
Service expense |
|
399,272 |
|
|
|
235,543 |
|
|
|
1,139,170 |
|
|
|
764,310 |
|
|
||||
General and administrative expense |
|
68,054 |
|
|
|
34,441 |
|
|
|
179,271 |
|
|
|
86,435 |
|
|
||||
Depreciation and amortization |
|
12,608 |
|
|
|
7,301 |
|
|
|
36,667 |
|
|
|
17,199 |
|
|
||||
Total operating expenses |
|
479,934 |
|
|
|
277,285 |
|
|
|
1,355,108 |
|
|
|
867,944 |
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||||||
Operating income |
|
13,125 |
|
|
|
43,334 |
|
|
|
69,509 |
|
|
|
102,222 |
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||||||
Other expenses (income): |
|
|
|
|
|
|
|
|
||||||||||||
Interest expense, net |
|
17,702 |
|
|
|
379 |
|
|
|
34,412 |
|
|
|
2,118 |
|
|
||||
Equity in net loss (income) of investee |
|
6,748 |
|
|
|
(10,325 |
) |
|
|
1,978 |
|
|
|
(12,200 |
) |
|
||||
Income (loss) from continuing operations before
|
|
(11,325 |
) |
|
|
53,280 |
|
|
|
33,119 |
|
|
|
112,304 |
|
|
||||
Provision (benefit) for income taxes |
|
(3,863 |
) |
|
|
14,360 |
|
|
|
7,944 |
|
|
|
19,785 |
|
|
||||
Income (loss) from continuing operations, net of
|
|
(7,462 |
) |
|
|
38,920 |
|
|
|
25,175 |
|
|
|
92,519 |
|
|
||||
Loss from discontinued operations, net of tax |
|
(108 |
) |
|
|
(115 |
) |
|
|
(232 |
) |
|
|
(618 |
) |
|
||||
Net income (loss) |
|
$ |
(7,570 |
) |
|
|
$ |
38,805 |
|
|
|
$ |
24,943 |
|
|
|
$ |
91,901 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Net income (loss) available to common
|
|
$ |
(7,570 |
) |
|
|
$ |
35,346 |
|
|
|
$ |
24,943 |
|
|
|
$ |
34,563 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Basic earnings (loss) per common share: |
|
|
|
|
|
|
|
|
||||||||||||
Continuing operations |
|
$ |
(0.53 |
) |
|
|
$ |
2.53 |
|
|
|
$ |
1.79 |
|
|
|
$ |
2.63 |
|
|
Discontinued operations |
|
(0.01 |
) |
|
|
(0.01 |
) |
|
|
(0.02 |
) |
|
|
(0.05 |
) |
|
||||
Basic earnings (loss) per common share |
|
$ |
(0.54 |
) |
|
|
$ |
2.52 |
|
|
|
$ |
1.77 |
|
|
|
$ |
2.58 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Diluted earnings (loss) per common share: |
|
|
|
|
|
|
|
|
||||||||||||
Continuing operations |
|
$ |
(0.53 |
) |
|
|
$ |
2.51 |
|
|
|
$ |
1.76 |
|
|
|
$ |
2.62 |
|
|
Discontinued operations |
|
(0.01 |
) |
|
|
(0.01 |
) |
|
|
(0.02 |
) |
|
|
(0.05 |
) |
|
||||
Diluted earnings (loss) per common share |
|
$ |
(0.54 |
) |
|
|
$ |
2.50 |
|
|
|
$ |
1.74 |
|
|
|
$ |
2.57 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Weighted-average number of common shares
|
|
|
|
|
|
|
|
|
||||||||||||
Basic |
|
13,993,438 |
|
|
|
14,026,039 |
|
|
|
14,102,371 |
|
|
|
13,367,605 |
|
|
||||
Diluted |
|
13,993,438 |
|
|
|
14,133,904 |
|
|
|
14,278,331 |
|
|
|
13,415,344 |
|
|
|
||||||||
Unaudited Condensed Consolidated Balance Sheets |
||||||||
(in thousands) |
||||||||
|
|
|
|
|
||||
|
|
|
|
|
||||
Assets |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
126,506 |
|
|
$ |
183,281 |
|
Accounts receivable, net |
|
289,230 |
|
|
197,943 |
|
||
Other current assets (1) |
|
54,775 |
|
|
44,634 |
|
||
Current assets of discontinued operations (2) |
|
141 |
|
|
758 |
|
||
Total current assets |
|
470,652 |
|
|
426,616 |
|
||
Operating lease right-of-use assets |
|
44,077 |
|
|
30,928 |
|
||
Property and equipment, net |
|
52,538 |
|
|
27,544 |
|
||
|
|
1,421,983 |
|
|
790,579 |
|
||
Equity investment |
|
134,353 |
|
|
137,466 |
|
||
Other assets |
|
11,550 |
|
|
12,780 |
|
||
Total assets |
|
$ |
2,135,153 |
|
|
$ |
1,425,913 |
|
|
|
|
|
|
||||
Liabilities and stockholders' equity |
||||||||
Current liabilities: |
|
|
|
|
||||
Accounts payable |
|
$ |
33,458 |
|
|
$ |
8,464 |
|
Accrued contract payables |
|
320,045 |
|
|
101,705 |
|
||
Accrued expenses and other current liabilities |
|
109,571 |
|
|
117,010 |
|
||
Accrued transportation costs |
|
92,028 |
|
|
79,674 |
|
||
Current portion of operating lease liabilities |
|
9,287 |
|
|
8,277 |
|
||
Other current liabilities (3) |
|
10,051 |
|
|
7,650 |
|
||
Current liabilities of discontinued operations (2) |
|
1,527 |
|
|
1,971 |
|
||
Total current liabilities |
|
575,967 |
|
|
324,751 |
|
||
Long-term debt, net of deferred financing costs |
|
974,669 |
|
|
485,980 |
|
||
Operating lease liabilities, less current portion |
|
35,389 |
|
|
23,437 |
|
||
Long-term contracts payables |
|
5,793 |
|
|
72,183 |
|
||
Other long-term liabilities (4) |
|
139,348 |
|
|
107,951 |
|
||
Total liabilities |
|
1,731,166 |
|
|
1,014,302 |
|
||
|
|
|
|
|
||||
Stockholders' equity |
|
403,987 |
|
|
411,611 |
|
||
Total liabilities and stockholders' equity |
|
$ |
2,135,153 |
|
|
$ |
1,425,913 |
|
(1) Includes other receivables, prepaid expenses and other current assets, and short-term restricted cash.
(2) Includes assets or liabilities related to WD Services' former Saudi Arabian operation.
(3) Includes deferred revenue and self-funded insurance programs.
(4) Includes other long-term liabilities and deferred tax liabilities.
|
||||||||||
Unaudited Condensed Consolidated Statements of Cash Flows |
||||||||||
(in thousands) |
||||||||||
|
|
|
|
|
||||||
|
|
Nine months ended |
||||||||
|
|
2021 |
|
2020 |
||||||
Operating activities |
|
|
|
|
||||||
Net income |
|
$ |
24,943 |
|
|
|
$ |
91,901 |
|
|
Depreciation and amortization |
|
36,666 |
|
|
|
17,199 |
|
|
||
Stock-based compensation |
|
4,225 |
|
|
|
2,949 |
|
|
||
Equity in net loss (income) of investee |
|
1,978 |
|
|
|
(12,200 |
) |
|
||
Deferred income taxes |
|
(3,295 |
) |
|
|
12,612 |
|
|
||
Reduction of right-of-use assets |
|
8,681 |
|
|
|
6,769 |
|
|
||
Other non-cash items (1) |
|
463 |
|
|
|
(2,847 |
) |
|
||
Changes in working capital (2) |
|
101,033 |
|
|
|
170,843 |
|
|
||
Net cash provided by operating activities |
|
174,694 |
|
|
|
287,226 |
|
|
||
|
|
|
|
|
||||||
Investing activities |
|
|
|
|
||||||
Purchase of property and equipment |
|
(13,852 |
) |
|
|
(4,786 |
) |
|
||
Acquisition, net of cash acquired |
|
(667,228 |
) |
|
|
(77,665 |
) |
|
||
Net cash used in investing activities |
|
(681,080 |
) |
|
|
(82,451 |
) |
|
||
|
|
|
|
|
||||||
Financing activities |
|
|
|
|
||||||
Proceeds from debt |
|
625,000 |
|
|
|
162,000 |
|
|
||
Repayment of debt |
|
(125,000 |
) |
|
|
(162,000 |
) |
|
||
Repurchase of common stock, for treasury |
|
(39,040 |
) |
|
|
(10,186 |
) |
|
||
Payment of debt issuance costs |
|
(13,486 |
) |
|
|
— |
|
|
||
Proceeds from common stock issued pursuant to stock option exercise |
|
3,099 |
|
|
|
21,581 |
|
|
||
Restricted stock surrendered for employee tax payment |
|
(851 |
) |
|
|
(92 |
) |
|
||
Preferred stock redemption payment |
|
— |
|
|
|
(88,743 |
) |
|
||
Preferred stock dividends |
|
— |
|
|
|
(1,988 |
) |
|
||
Other financing activities |
|
— |
|
|
|
(204 |
) |
|
||
Net cash provided by (used in) financing activities |
|
449,722 |
|
|
|
(79,632 |
) |
|
||
|
|
|
|
|
||||||
Net change in cash, cash equivalents and restricted cash |
|
(56,664 |
) |
|
|
125,143 |
|
|
||
Cash, cash equivalents and restricted cash at beginning of period |
|
183,356 |
|
|
|
61,673 |
|
|
||
Cash, cash equivalents and restricted cash at end of period |
|
$ |
126,692 |
|
|
|
$ |
186,816 |
|
|
(1) Includes provision for doubtful accounts and amortization of deferred financing costs and debt discount.
(2) Includes accounts receivable and other receivables, prepaid expenses and other assets, self-funded insurance programs, income tax refunds on sale of business, accrued contract payables, accounts payable and accrued expenses, accrued transportation costs, deferred revenue and other long-term liabilities.
|
|||||||||||||||||||||||
Unaudited Reconciliation of Non-GAAP Financial Measures |
|||||||||||||||||||||||
Segment Information and Adjusted EBITDA |
|||||||||||||||||||||||
(in thousands) |
|||||||||||||||||||||||
|
|
Three months ended |
|||||||||||||||||||||
|
|
NEMT |
|
Personal
|
|
RPM |
|
Matrix
|
|
Total
|
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Service revenue, net |
$ |
372,992 |
|
|
|
$ |
118,503 |
|
|
$ |
1,564 |
|
|
$ |
— |
|
|
|
$ |
493,059 |
|
|
|
Grant income |
— |
|
|
|
— |
|
|
— |
|
|
— |
|
|
|
— |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
||||||||||||||
Service expense |
304,398 |
|
|
|
94,107 |
|
|
767 |
|
|
— |
|
|
|
399,272 |
|
|
||||||
General and administrative expense |
52,118 |
|
|
|
15,720 |
|
|
216 |
|
|
— |
|
|
|
68,054 |
|
|
||||||
Depreciation and amortization |
7,496 |
|
|
|
4,912 |
|
|
200 |
|
|
— |
|
|
|
12,608 |
|
|
||||||
Total operating expenses |
364,012 |
|
|
|
114,739 |
|
|
1,183 |
|
|
— |
|
|
|
479,934 |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Operating income |
8,980 |
|
|
|
3,764 |
|
|
381 |
|
|
— |
|
|
|
13,125 |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Other expenses (income): |
|
|
|
|
|
|
|
|
|
||||||||||||||
Interest expense, net |
17,702 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
|
17,702 |
|
|
||||||
Equity in net loss of investee |
— |
|
|
|
— |
|
|
— |
|
|
6,748 |
|
|
|
6,748 |
|
|
||||||
Income (loss) from continuing operations |
|
|
|
|
|
|
|
|
|
||||||||||||||
before income taxes |
(8,722 |
) |
|
|
3,764 |
|
|
381 |
|
|
(6,748 |
) |
|
|
(11,325 |
) |
|
||||||
Provision (benefit) for income taxes |
(2,931 |
) |
|
|
864 |
|
|
107 |
|
|
(1,903 |
) |
|
|
(3,863 |
) |
|
||||||
Income (loss) from continuing operations, net of
|
(5,791 |
) |
|
|
2,900 |
|
|
274 |
|
|
(4,845 |
) |
|
|
(7,462 |
) |
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Interest expense, net |
17,702 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
|
17,702 |
|
|
||||||
Provision (benefit) for income taxes |
(2,931 |
) |
|
|
864 |
|
|
107 |
|
|
(1,903 |
) |
|
|
(3,863 |
) |
|
||||||
Depreciation and amortization |
7,496 |
|
|
|
4,912 |
|
|
200 |
|
|
— |
|
|
|
12,608 |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
EBITDA |
16,476 |
|
|
|
8,676 |
|
|
581 |
|
|
(6,748 |
) |
|
|
18,985 |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Restructuring and related charges (1) |
3,087 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
|
3,087 |
|
|
||||||
Transaction costs (2) |
10,115 |
|
|
|
1,177 |
|
|
— |
|
|
— |
|
|
|
11,292 |
|
|
||||||
Cash settled equity |
2,599 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
|
2,599 |
|
|
||||||
Stock-based compensation |
1,217 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
|
1,217 |
|
|
||||||
COVID-19 related costs, net of grant income |
165 |
|
|
|
228 |
|
|
— |
|
|
— |
|
|
|
393 |
|
|
||||||
Equity in net loss of investee |
— |
|
|
|
— |
|
|
— |
|
|
6,748 |
|
|
|
6,748 |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Adjusted EBITDA |
$ |
33,659 |
|
|
|
$ |
10,081 |
|
|
$ |
581 |
|
|
$ |
— |
|
|
|
$ |
44,321 |
|
|
(1) Restructuring and related charges include professional services costs.
(2) Transaction costs include Circulation management incentive plan ("MIP") costs and certain transaction-related expenses.
|
||||||||||||||
Unaudited Reconciliation of Non-GAAP Financial Measures |
||||||||||||||
Segment Information and Adjusted EBITDA |
||||||||||||||
(in thousands) |
||||||||||||||
|
|
Three months ended |
||||||||||||
|
|
NEMT |
|
Matrix
|
|
Total
|
||||||||
|
|
|
|
|
|
|
||||||||
Service revenue, net |
$ |
320,619 |
|
|
$ |
— |
|
|
|
$ |
320,619 |
|
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses: |
|
|
|
|
|
|||||||||
Service expense |
235,543 |
|
|
— |
|
|
|
235,543 |
|
|
||||
General and administrative expense |
34,441 |
|
|
— |
|
|
|
34,441 |
|
|
||||
Depreciation and amortization |
7,301 |
|
|
— |
|
|
|
7,301 |
|
|
||||
Total operating expenses |
277,285 |
|
|
— |
|
|
|
277,285 |
|
|
||||
|
|
|
|
|
|
|
||||||||
Operating income |
43,334 |
|
|
— |
|
|
|
43,334 |
|
|
||||
|
|
|
|
|
|
|
||||||||
Other expenses (income): |
|
|
|
|
|
|||||||||
Interest expense, net |
379 |
|
|
— |
|
|
|
379 |
|
|
||||
Equity in net income of investee |
— |
|
|
(10,325 |
) |
|
|
(10,325 |
) |
|
||||
Income from continuing |
|
|
|
|
|
|||||||||
operations before income taxes |
42,955 |
|
|
10,325 |
|
|
|
53,280 |
|
|
||||
Provision for income taxes |
11,774 |
|
|
2,586 |
|
|
|
14,360 |
|
|
||||
Income from continuing operations, net
|
31,181 |
|
|
7,739 |
|
|
|
38,920 |
|
|
||||
|
|
|
|
|
|
|
||||||||
Interest expense, net |
379 |
|
|
— |
|
|
|
379 |
|
|
||||
Provision for income taxes |
11,774 |
|
|
2,586 |
|
|
|
14,360 |
|
|
||||
Depreciation and amortization |
7,301 |
|
|
— |
|
|
|
7,301 |
|
|
||||
|
|
|
|
|
|
|
||||||||
EBITDA |
50,635 |
|
|
10,325 |
|
|
|
60,960 |
|
|
||||
|
|
|
|
|
|
|
||||||||
Restructuring and related charges (1) |
969 |
|
|
— |
|
|
|
969 |
|
|
||||
Transaction costs (2) |
3,579 |
|
|
— |
|
|
|
3,579 |
|
|
||||
Cash settled equity (3) |
2,894 |
|
|
|
|
2,894 |
|
|
||||||
Stock-based compensation (3) |
1,139 |
|
|
— |
|
|
|
1,139 |
|
|
||||
COVID-19 related costs |
118 |
|
|
— |
|
|
|
118 |
|
|
||||
Equity in net income of investee |
— |
|
|
(10,325 |
) |
|
|
(10,325 |
) |
|
||||
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA |
$ |
59,334 |
|
|
$ |
— |
|
|
|
$ |
59,334 |
|
|
(1) Restructuring and related charges include severance and office closure costs of
(2) Transaction costs include Circulation management incentive plan ("MIP") costs and certain transaction-related expenses.
(3) Adjusted EBITDA for Q3 of 2020 was recast to show the impact of stock-based compensation and cash settled equity, which the Company is now including for purposes of this calculation.
|
|||||||||||||||||||||||
Unaudited Reconciliation of Non-GAAP Financial Measures |
|||||||||||||||||||||||
Segment Information and Adjusted EBITDA |
|||||||||||||||||||||||
(in thousands) |
|||||||||||||||||||||||
|
|
Nine months ended |
|||||||||||||||||||||
|
|
NEMT |
|
Personal
|
|
RPM |
|
Matrix
|
|
Total
|
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Service revenue, net |
$ |
1,081,168 |
|
|
$ |
338,385 |
|
|
|
$ |
1,564 |
|
|
$ |
— |
|
|
|
$ |
1,421,117 |
|
|
|
Grant income |
— |
|
|
3,500 |
|
|
|
— |
|
|
— |
|
|
|
3,500 |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
||||||||||||||
Service expense |
869,470 |
|
|
268,933 |
|
|
|
767 |
|
|
— |
|
|
|
1,139,170 |
|
|
||||||
General and administrative expense |
133,706 |
|
|
45,349 |
|
|
|
216 |
|
|
— |
|
|
|
179,271 |
|
|
||||||
Depreciation and amortization |
21,744 |
|
|
14,723 |
|
|
|
200 |
|
|
— |
|
|
|
36,667 |
|
|
||||||
Total operating expenses |
1,024,920 |
|
|
329,005 |
|
|
|
1,183 |
|
|
— |
|
|
|
1,355,108 |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Operating income |
56,248 |
|
|
12,880 |
|
|
|
381 |
|
|
— |
|
|
|
69,509 |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Other expenses (income): |
|
|
|
|
|
|
|
|
|
||||||||||||||
Interest expense, net |
34,412 |
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
34,412 |
|
|
||||||
Equity in net loss of investee |
— |
|
|
— |
|
|
|
— |
|
|
1,978 |
|
|
|
1,978 |
|
|
||||||
Income (loss) from continuing operations |
|
|
|
|
|
|
|
|
|
||||||||||||||
before income taxes |
21,836 |
|
|
12,880 |
|
|
|
381 |
|
|
(1,978 |
) |
|
|
33,119 |
|
|
||||||
Provision (benefit) for income taxes |
5,027 |
|
|
3,364 |
|
|
|
107 |
|
|
(554 |
) |
|
|
7,944 |
|
|
||||||
Income (loss) from continuing operations,
|
16,809 |
|
|
9,516 |
|
|
|
274 |
|
|
(1,424 |
) |
|
|
25,175 |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Interest expense, net |
34,412 |
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
34,412 |
|
|
||||||
Provision for income taxes |
5,027 |
|
|
3,364 |
|
|
|
107 |
|
|
(554 |
) |
|
|
7,944 |
|
|
||||||
Depreciation and amortization |
21,744 |
|
|
14,723 |
|
|
|
200 |
|
|
— |
|
|
|
36,667 |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
EBITDA |
77,992 |
|
|
27,603 |
|
|
|
581 |
|
|
(1,978 |
) |
|
|
104,198 |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Restructuring and related charges (1) |
11,215 |
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
11,215 |
|
|
||||||
Transaction costs (2) |
14,969 |
|
|
3,467 |
|
|
|
— |
|
|
— |
|
|
|
18,436 |
|
|
||||||
Cash settled equity |
9,145 |
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
9,145 |
|
|
||||||
Stock-based compensation |
3,707 |
|
|
76 |
|
|
|
— |
|
|
— |
|
|
|
3,783 |
|
|
||||||
COVID-19 related costs, net of grant income |
618 |
|
|
(1,871 |
) |
|
|
— |
|
|
— |
|
|
|
(1,253 |
) |
|
||||||
Equity in net income of investee |
— |
|
|
— |
|
|
|
— |
|
|
1,978 |
|
|
|
1,978 |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Adjusted EBITDA |
$ |
117,646 |
|
|
$ |
29,275 |
|
|
|
$ |
581 |
|
|
$ |
— |
|
|
|
$ |
147,502 |
|
|
(1) Restructuring and related charges include professional services costs of
(2) Transaction costs include Circulation management incentive plan ("MIP") costs and certain transaction-related expenses.
|
||||||||||||||
Unaudited Reconciliation of Non-GAAP Financial Measures |
||||||||||||||
Segment Information and Adjusted EBITDA |
||||||||||||||
(in thousands) |
||||||||||||||
|
|
Nine months ended |
||||||||||||
|
|
NEMT |
|
Matrix
|
|
Total
|
||||||||
|
|
|
|
|
|
|
||||||||
Service revenue, net |
$ |
970,166 |
|
|
$ |
— |
|
|
|
$ |
970,166 |
|
|
|
Grant income |
— |
|
|
— |
|
|
|
— |
|
|
||||
|
|
|
|
|
|
|
||||||||
Operating expenses: |
|
|
|
|
|
|||||||||
Service expense |
764,310 |
|
|
— |
|
|
|
764,310 |
|
|
||||
General and administrative expense |
86,435 |
|
|
— |
|
|
|
86,435 |
|
|
||||
Depreciation and amortization |
17,199 |
|
|
— |
|
|
|
17,199 |
|
|
||||
Total operating expenses |
867,944 |
|
|
— |
|
|
|
867,944 |
|
|
||||
|
|
|
|
|
|
|
||||||||
Operating income |
102,222 |
|
|
— |
|
|
|
102,222 |
|
|
||||
|
|
|
|
|
|
|
||||||||
Other expenses (income): |
|
|
|
|
|
|||||||||
Interest expense, net |
2,118 |
|
|
— |
|
|
|
2,118 |
|
|
||||
Equity in net income of investee |
— |
|
|
(12,200 |
) |
|
|
(12,200 |
) |
|
||||
Income from continuing |
|
|
|
|
|
|||||||||
operations before income taxes |
100,104 |
|
|
12,200 |
|
|
|
112,304 |
|
|
||||
Provision for income taxes |
16,730 |
|
|
3,055 |
|
|
|
19,785 |
|
|
||||
Income from continuing operations, net of
|
83,374 |
|
|
9,145 |
|
|
|
92,519 |
|
|
||||
|
|
|
|
|
|
|
||||||||
Interest expense, net |
2,118 |
|
|
— |
|
|
|
2,118 |
|
|
||||
Provision for income taxes |
16,730 |
|
|
3,055 |
|
|
|
19,785 |
|
|
||||
Depreciation and amortization |
17,199 |
|
|
— |
|
|
|
17,199 |
|
|
||||
|
|
|
|
|
|
|
||||||||
EBITDA |
119,421 |
|
|
12,200 |
|
|
|
131,621 |
|
|
||||
|
|
|
|
|
|
|
||||||||
Restructuring and related charges (1) |
3,277 |
|
|
— |
|
|
|
3,277 |
|
|
||||
Transaction costs (2) |
4,700 |
|
|
— |
|
|
|
4,700 |
|
|
||||
Cash settled equity (3) |
6,891 |
|
|
— |
|
|
|
6,891 |
|
|
||||
Stock-based compensation (3) |
2,834 |
|
|
— |
|
|
|
2,834 |
|
|
||||
COVID-19 related costs, net of grant income |
349 |
|
|
— |
|
|
|
349 |
|
|
||||
Equity in net (income) loss of investee |
— |
|
|
(12,200 |
) |
|
|
(12,200 |
) |
|
||||
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA |
$ |
137,472 |
|
|
$ |
— |
|
|
|
$ |
137,472 |
|
|
(1) Restructuring and related charges include severance and office closure costs of
(2) Transaction costs include Circulation MIP and certain transaction-related expenses.
(3) Adjusted EBITDA for the nine months ended
|
|||||||||||||||||
Unaudited Summary Financial Information of |
|||||||||||||||||
(in thousands) |
|||||||||||||||||
|
Three months ended |
|
Nine months ended |
||||||||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||||
Revenue |
$ |
78,458 |
|
|
|
$ |
140,728 |
|
|
$ |
316,830 |
|
|
|
$ |
292,699 |
|
Operating expense |
87,324 |
|
|
|
94,509 |
|
|
288,883 |
|
|
|
213,219 |
|
||||
Depreciation and amortization |
7,921 |
|
|
|
10,730 |
|
|
24,497 |
|
|
|
30,406 |
|
||||
Operating income (loss) |
(16,787 |
) |
|
|
35,489 |
|
|
3,450 |
|
|
|
49,074 |
|
||||
|
|
|
|
|
|
|
|
||||||||||
Interest expense, net |
4,337 |
|
|
|
4,545 |
|
|
12,502 |
|
|
|
15,264 |
|
||||
Provision (benefit) for income taxes |
(5,497 |
) |
|
|
9,562 |
|
|
(1,909 |
) |
|
|
9,893 |
|
||||
Net income (loss) |
(15,627 |
) |
|
|
21,382 |
|
|
(7,143 |
) |
|
|
23,917 |
|
||||
|
|
|
|
|
|
|
|
||||||||||
Equity Interest |
43.6 |
|
% |
|
43.6 |
% |
|
43.6 |
|
% |
|
43.6 |
% |
||||
Net income (loss) - |
(6,813 |
) |
|
|
9,318 |
|
|
(3,114 |
) |
|
|
10,423 |
|
||||
Management fee and other |
65 |
|
|
|
1,007 |
|
|
1,136 |
|
|
|
1,777 |
|
||||
Equity in net income (loss) of
|
$ |
(6,748 |
) |
|
|
$ |
10,325 |
|
|
$ |
(1,978 |
) |
|
|
$ |
12,200 |
|
|
|
|
|
|
|
|
|
||||||||||
Cash |
$ |
74,958 |
|
|
|
$ |
67,560 |
|
|
|
|
|
|||||
Net Debt (2) |
$ |
244,317 |
|
|
|
$ |
322,575 |
|
|
|
|
|
(1) The results of our equity method investment are excluded from the calculation of
(2) Net debt represents long-term debt including the current portion, excluding deferred financing costs, less cash.
|
|||||||||||||||||
Unaudited Reconciliation of Non-GAAP Financial Measures |
|||||||||||||||||
Adjusted EBITDA: Matrix Medical Network (1) |
|||||||||||||||||
(in thousands) |
|||||||||||||||||
|
Three months ended |
|
Nine months ended |
||||||||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||||
Revenue |
$ |
78,458 |
|
|
|
$ |
140,728 |
|
|
$ |
316,830 |
|
|
|
$ |
292,699 |
|
Operating expense |
87,324 |
|
|
|
94,509 |
|
|
288,883 |
|
|
|
213,219 |
|
||||
Depreciation and amortization |
7,921 |
|
|
|
10,730 |
|
|
24,497 |
|
|
|
30,406 |
|
||||
Operating income (loss) |
(16,787 |
) |
|
|
35,489 |
|
|
3,450 |
|
|
|
49,074 |
|
||||
|
|
|
|
|
|
|
|
||||||||||
Interest expense, net |
4,337 |
|
|
|
4,545 |
|
|
12,502 |
|
|
|
15,264 |
|
||||
Provision (benefit) for income taxes |
(5,497 |
) |
|
|
9,562 |
|
|
(1,909 |
) |
|
|
9,893 |
|
||||
Net income (loss) |
(15,627 |
) |
|
|
21,382 |
|
|
(7,143 |
) |
|
|
23,917 |
|
||||
|
|
|
|
|
|
|
|
||||||||||
Depreciation and amortization |
7,921 |
|
|
|
10,730 |
|
|
24,497 |
|
|
|
30,406 |
|
||||
Interest expense |
4,337 |
|
|
|
4,545 |
|
|
12,502 |
|
|
|
15,264 |
|
||||
Provision (benefit) for income taxes |
(5,497 |
) |
|
|
9,562 |
|
|
(1,909 |
) |
|
|
9,893 |
|
||||
EBITDA |
(8,866 |
) |
|
|
46,219 |
|
|
27,947 |
|
|
|
79,480 |
|
||||
Management fees |
132 |
|
|
|
2,169 |
|
|
2,424 |
|
|
|
3,838 |
|
||||
Integration costs |
14 |
|
|
|
— |
|
|
169 |
|
|
|
— |
|
||||
Severance costs |
1,136 |
|
|
|
286 |
|
|
1,368 |
|
|
|
1,223 |
|
||||
Restructuring expense |
7,476 |
|
|
|
3,781 |
|
|
17,691 |
|
|
|
3,781 |
|
||||
COVID-19 related costs |
216 |
|
|
|
1,507 |
|
|
1,163 |
|
|
|
6,599 |
|
||||
Transaction costs |
2,522 |
|
|
|
297 |
|
|
6,945 |
|
|
|
2,051 |
|
||||
Adjusted EBITDA |
$ |
2,630 |
|
|
|
$ |
54,259 |
|
|
$ |
57,707 |
|
|
|
$ |
96,972 |
|
(1) ModivCare accounts for its proportionate share of Matrix's results using the equity method. Matrix's Adjusted EBITDA is not included within
|
||||||||||||||||||||
Unaudited Reconciliation of Non-GAAP Financial Measures |
||||||||||||||||||||
Adjusted Net Income and Adjusted Net Income per Common Share: |
||||||||||||||||||||
(in thousands, except share and per share data) |
||||||||||||||||||||
|
|
Three months ended |
|
Nine months ended |
||||||||||||||||
|
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||
Income (loss) from continuing operations, net of tax |
$ |
(7,462 |
) |
|
|
$ |
38,920 |
|
|
|
$ |
25,175 |
|
|
|
$ |
92,519 |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Restructuring and related charges(1) |
3,087 |
|
|
|
969 |
|
|
|
11,215 |
|
|
|
3,277 |
|
|
|||||
Transaction costs(2) |
11,292 |
|
|
|
3,579 |
|
|
|
18,436 |
|
|
|
4,700 |
|
|
|||||
Cash settled equity(3) |
2,599 |
|
|
|
2,894 |
|
|
|
9,145 |
|
|
|
6,891 |
|
|
|||||
Stock-based compensation(3) |
1,217 |
|
|
|
1,139 |
|
|
|
3,783 |
|
|
|
2,834 |
|
|
|||||
Equity in net loss (income) of investee |
6,748 |
|
|
|
(10,325 |
) |
|
|
1,978 |
|
|
|
(12,200 |
) |
|
|||||
Intangible amortization expense |
9,177 |
|
|
|
4,884 |
|
|
|
27,827 |
|
|
|
10,219 |
|
|
|||||
Transaction-related financing expense |
6,630 |
|
|
|
— |
|
|
|
6,630 |
|
|
|
— |
|
|
|||||
COVID-19 related costs, net of grant income |
393 |
|
|
|
118 |
|
|
|
(1,253 |
) |
|
|
349 |
|
|
|||||
Tax impact of the CARES Act |
— |
|
|
|
— |
|
|
|
— |
|
|
|
(10,984 |
) |
|
|||||
Tax effected impact of adjustments |
(10,647 |
) |
|
|
98 |
|
|
|
(20,577 |
) |
|
|
(1,733 |
) |
|
|||||
|
|
|
|
|
|
|
|
|
||||||||||||
Adjusted Net Income |
$ |
23,034 |
|
|
|
$ |
42,276 |
|
|
|
$ |
82,359 |
|
|
|
$ |
95,872 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Dividends on convertible preferred stock |
— |
|
|
|
(27 |
) |
|
|
— |
|
|
|
(1,988 |
) |
|
|||||
Income allocated to participating securities |
— |
|
|
|
(264 |
) |
|
|
— |
|
|
|
(7,052 |
) |
|
|||||
|
|
|
|
|
|
|
|
|
||||||||||||
Adjusted Net Income available to common stockholders |
$ |
23,034 |
|
|
|
$ |
41,985 |
|
|
|
$ |
82,359 |
|
|
|
$ |
86,832 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Adjusted earnings per share |
$ |
1.63 |
|
|
|
$ |
2.97 |
|
|
|
$ |
5.77 |
|
|
|
$ |
6.47 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Diluted weighted-average number of common shares
|
14,161,806 |
|
|
|
14,133,904 |
|
|
|
14,278,331 |
|
|
|
13,415,344 |
|
|
(1) Restructuring and related charges include severance and office closure costs and professional services.
(2) Transaction costs include the MIP related to the Circulation acquisition and certain other transaction-related expenses.
(3) Adjusted net income for the three and nine months ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20211105005319/en/
Investor Relations
(212) 836-9614
kahl@equityny.com
Source:
FAQ
What were ModivCare's financial results for Q3 2021?
What is the significance of the recent acquisitions by ModivCare?
How did ModivCare's Adjusted EBITDA perform in Q3 2021?
What was the cash position of ModivCare at the end of Q3 2021?